Aurobindo Pharma Limited, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), has received registrations from the Medicines Control Council (MCC) to manufacture and market three products in South Africa.
With these three approvals – Auro-Cefepime injectables in 500mg, 100mg and 2,000mg strengths and Loxip 250mg and 500mg under anti-infective category, and Keysal 5mg and 10mg under the cardiovascular system category – Aurobindo now has 41 registrations approved by the MCC, the company said in a press release on Thursday.
